The newest generation of antiobesity medications (AOMs)—GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), dual action GLP-1/GIP combinations, triple action injectables, and emerging injectable and oral medications—have changed the landscape for weight management, bringing weight loss success to many for whom weight maintenance had previously not been possible.
Trending
- Early Diabetes Treatment Makes a Measurable Difference
- New Research Raises Concerns About Metformin
- Using Metabolites for Predicting Early Prediabetes Risk
- 2025 November/December Product Spotlight
- A Critical Look at Osteoporosis
- Cognitive Performance Nutrition
- RDs Shaping AI in the Field of Nutrition
- CPE Monthly: Vitamin D in Diabetes